Abstract:Antibiotic therapy effectively addresses Escherichia coli-induced enteric diseases, but its excessive utilization results in microbial imbalance and heightened resistance. This study evaluates the therapeutic efficacy of orally administered poly (lactic-co-glycolic acid) (PLGA)-loaded antimicrobial peptide OH-CATH30 microspheres in murine bacterial enteritis. Mice were categorized into the healthy control group (CG), untreated model group (MG), OH-CATH30 treatment group (OC), PLGA-OH-CATH30 treatment group (POC), and gentamicin sulfate treatment group (GS). Except for the control group, all other experimental groups underwent Escherichia coli-induced enteritis, followed by a 5-day treatment period. The evaluation encompassed clinical symptoms, intestinal morphology, blood parameters, inflammatory response, and gut microbiota. PLGA-OH-CATH30 microspheres significantly alleviated weight loss and intestinal damage while also reducing the infection-induced increase in spleen index. Furthermore, these microspheres normalized white blood cell count and neutrophil ratio, suppressed inflammatory factors (IL-1β, IL-6, and TNF-α), and elevated the anti-inflammatory factor IL-10. Analysis of 16S rRNA sequencing results demonstrated that microsphere treatment increased the abundance of beneficial bacteria, including Phocaeicola vulgatus, in the intestinal tract while concurrently decreasing the abundance of pathogenic bacteria, such as Escherichia. In conclusion, PLGA-OH-CATH30 microspheres have the potential to ameliorate intestinal damage and modulate the intestinal microbiota, making them a promising alternative to antibiotics for treating enteric diseases induced by Escherichia coli.

What problem does this paper attempt to address?

### Problems the paper attempts to solve This paper aims to explore the efficacy of poly(lactic - co - glycolic acid) (PLGA) - loaded antimicrobial peptide OH - CATH30 microspheres in the oral treatment of intestinal inflammation caused by Escherichia coli. Specifically, researchers hope to solve the existing problems in current antibiotic treatment of intestinal diseases through the following aspects: 1. **Reduce microbial imbalance and drug resistance**: - The overuse of antibiotics has led to the imbalance of the microbial community and the increase of drug resistance. Researchers hope to reduce these problems by using PLGA - OH - CATH30 microspheres. 2. **Improve treatment efficacy**: - Evaluate the treatment efficacy of PLGA - OH - CATH30 microspheres in a mouse model of intestinal inflammation caused by Escherichia coli, including changes in clinical symptoms, intestinal morphology, blood parameters, inflammatory response, and intestinal microbiota. 3. **Improve the intestinal microbiota**: - Investigate whether PLGA - OH - CATH30 microspheres can regulate the intestinal microbiota, increase the number of beneficial bacteria, and reduce the number of pathogenic bacteria, thereby improving intestinal health. 4. **Explore new treatment methods as alternatives to antibiotics**: - In view of the increasingly serious antibiotic resistance, researchers hope to find an effective alternative method to deal with intestinal diseases caused by Escherichia coli. ### Main research contents - **Experimental design**: - Mice were divided into five groups: the healthy control group (CG), the untreated model group (MG), the OH - CATH30 treatment group (OC), the PLGA - OH - CATH30 treatment group (POC), and the gentamicin sulfate treatment group (GS). - Except for the control group, mice in other groups were induced with intestinal inflammation by Escherichia coli and then treated for 5 days. - **Evaluation indicators**: - Changes in clinical symptoms, body weight, intestinal morphology, blood parameters, inflammatory response, and intestinal microbiota. - **Main findings**: - PLGA - OH - CATH30 microspheres significantly alleviated body weight loss and intestinal damage and reduced the increase in spleen index caused by infection. - In the microsphere - treated group, the white blood cell count and neutrophil proportion in mice returned to normal, the expression of inflammatory factors (IL - 1β, IL - 6, and TNF - α) was inhibited, and the level of anti - inflammatory factor IL - 10 was increased. - The results of 16S rRNA sequencing showed that microsphere treatment increased the abundance of beneficial bacteria (such as Phocaeicola vulgatus) in the intestine while reducing the abundance of pathogenic bacteria (such as Escherichia coli). ### Conclusion PLGA - OH - CATH30 microspheres show good efficacy in treating intestinal inflammation caused by Escherichia coli, can improve intestinal damage and regulate the intestinal microbiota, and are expected to become an alternative therapy to antibiotics.

Exploring PLGA-OH-CATH30 Microspheres for Oral Therapy of Escherichia coli-Induced Enteritis

Cytoprotective Effects of <i>Lactobacilli</i> on Mouse Epithelial Cells during <i>Salmonella</i> Infection

Evaluation of Probiotic and Antimicrobial Potential of Canine Derived–<em>Lactobacilli</em>

Modulation of Lactobacillus Rhamnosus GG on the Gut Microbiota and Metabolism in Mice with Clostridioides Difficile Infection

Functional Effects of Probiotic Lactiplantibacillus plantarum in Alleviation Multidrug-Resistant Escherichia coli–Associated Colitis in BALB/c Mice Model

Oral Administration of the Antimicrobial Peptide Mastoparan X Alleviates Enterohemorrhagic Escherichia Coli–induced Intestinal Inflammation and Regulates the Gut Microbiota

Gut microbiota modulation and anti-inflammatory properties of mixed lactobacilli in dextran sodium sulfate-induced colitis in mice

Lactobacillus plantarum and Lactobacillus brevis Alleviate Intestinal Inflammation and Microbial Disorder Induced by ETEC in a Murine Model

Protective effect of plantaricin bio-LP1 bacteriocin on multidrug-resistance Escherichia Coli infection by alleviate the inflammation and modulate of gut-microbiota in BALB/c mice model

Programmable probiotics modulate inflammation and gut microbiota for inflammatory bowel disease treatment after effective oral delivery

Regulatory Effect of Lactiplantibacillus plantarum 2-33 on Intestinal Microbiota of Mice With Antibiotic-Associated Diarrhea

Optimization of a gelatin/carboxymethylcellulose-based probiotic microcapsule and its application in preventing dextran sodium sulfate-induced colitis in mice.

Effects of Bacteroides-Based Microecologics against Antibiotic-Associated Diarrhea in Mice

Chitosan-coated PLGA microemulsion loaded with tannic acid against Escherichia coli in vitro and in vivo

PLGA microspheres carrying EMSCs-CM for the effective treatment of murine ulcerative colitis

Antimicrobial Peptide MPX&nbsp;Against Escherichia Coli O157:H7&nbsp;Infection and Inhibiting inﬂammation, Enhancing Epithelial Barrier and Promoting Nutrient Absorption in the Intestine

Bifidobacterium Longum, Lactobacillus Plantarum and Pediococcus Acidilactici Reversed ETEC-Inducing Intestinal Inflammation in Mice

Nanozyme-Enhanced Probiotic Spores Regulate the Intestinal Microenvironment for Targeted Acute Gastroenteritis Therapy.

Synthesis and antibacterial activity of FST and its effects on inflammatory response and intestinal barrier function in mice infected with Escherichia coli O78

Alleviating effect of Lactobacillus pentosus CQZC01 probiotic strain on antibiotic-induced diarrhea in mice

Assessing the Efficacy of PLGA-Loaded Antimicrobial Peptide OH-CATH30 Microspheres for the Treatment of Bacterial Keratitis: A Promising Approach